|
| Press Releases |
|
 |
|
| Friday, May 29, 2015 |
|
|
AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA, a Fully Human Anti-TNF-alpha Monoclonal Antibody, in the Treatment of Ankylosing Spondylitis |
| AbbVie GK and Eisai Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of HUMIRA Pre-filled Syringe 40 mg / 0.8 mL, a fully human anti-TNF-alpha monoclonal antibody formulation, has been lifted for use in patients with ankylosing spondylitis. more info >> |
|
| Wednesday, May 27, 2015 |
|
|
Eisai Submits New Drug Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis in Japan |
| Eisai Co., Ltd. announced today that it has submitted a new drug application for mecobalamin (development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan. more info >> |
|
|
Eisai Receives Positive CHMP Opinion on Indication Expansion for Antiepileptic Agent Fycompa (Perampanel) as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the use of Fycompa (perampanel) for the adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in adult and adolescent patients from 12 years of age with idiopathic generalized epilepsy. more info >> |
|
| Thursday, May 21, 2015 |
|
|
Eisai to Promote Clinical Trial Data Disclosure for The Advancement of Science and Medicine |
| Eisai Co., Ltd. has announced today that, in order to further promote transparency in clinical trial data disclosure, it has determined its policy on clinical trial data disclosure and is making clinical trial data publicly available to researchers via an external website (www.clinicalstudydatarequest.com). more info >> |
|
| Wednesday, May 20, 2015 |
|
|
Eisai Launches In-house Developed Novel Anticancer Agent Lenvima (Lenvatinib Mesylate) as Treatment for Unresectable Thyroid Cancer in Japan |
| Eisai Co., Ltd. announced that it has launched its in-house developed novel anticancer agent Lenvima Capsule 4 mg and 10 mg as a treatment for unresectable thyroid cancer in Japan on May 20, 2015. more info >> |
|
| Thursday, May 14, 2015 |
|
|
Eisai to Present New Research on Oncology Products and Pipeline at 51st ASCO Annual Meeting |
Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 29 to June 2, 2015.
more info >> |
|
| Monday, April 27, 2015 |
|
|
Eisai and Nihon Medi-Physics Enter Collaboration Agreement to Contribute to Diagnosis and Treatment of Dementia with Lewy Bodies |
| Eisai Co., Ltd. and Nihon Medi-Physics Co., Ltd. announced today that they have entered into a collaboration agreement to contribute to the diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan. more info >> |
|
| Monday, April 13, 2015 |
|
|
Eisai and Genomics Plc to Collaborate in Analyses of Large-Scale Genotype/Phenotype Data to Inform Drug Development |
| Eisai Co., Ltd. and Genomics plc announced today that they have entered into a collaborative agreement to use Genomics' sophisticated statistical analyses of large-scale multi-phenotype genetic association data to inform Eisai's drug discovery process, including target selection, target validation, indication selection and repositioning. more info >> |
|
| Friday, April 3, 2015 |
|
|
Niigata University and Eisai Present Results of Joint Research in U.S. Academic Journal |
| A research group led by Professor Takeshi Ikeuchi of the Department of Molecular Genetics within the Brain Research Institute at Niigata University and Eisai Co., Ltd. announced today that the amount of plasma desmosterol was found to be highly correlated with longitudinal cognitive decline in patients with Alzheimer's disease. more info >> |
|
| Thursday, March 5, 2015 |
|
|
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer |
Eisai Co., Ltd. and Merck announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck's anti-D-1 therapy, pembrolizumab in combination with Eisai oncology compounds lenvatinib mesylate and eribulin mesylate in multiple clinical trials.
more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Mazda Unveils MAZDA CX-6e New Battery EV in World Premiere
Jan 12, 2026 13:10 JST
|
|
|
Argentine Football Association (AFA) teams with Verofax to offer AI Experiences to Fans 
Jan 12, 2026 10:00 HKT/SGT
|
|
|
Metaspacex Limited Partners with Popcorn Technology to Expand into Web3.0 Digital Finance
Jan 11, 2026 20:59 HKT/SGT
|
|
|
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
Jan 10, 2026 07:00 HKT/SGT
|
|
|
TOYOTA GAZOO Racing Announces GR Yaris MORIZO RR
Jan 9, 2026 16:03 JST
|
|
|
Honda Announces New Lines of Models that Represent "Honda Sports DNA" at Tokyo Auto Salon 2026
Jan 9, 2026 14:24 JST
|
|
|
Honda Launches Fixed-Battery Electric Two-Wheeled Personal Commuter "Honda UC3" in Thailand and Vietnam
Jan 9, 2026 13:27 JST
|
|
|
Sponsorship Agreement Reached with LCR Honda; Full-Season MotoGP Entry as Pro Honda LCR
Jan 9, 2026 13:05 JST
|
|
|
Mazda Develops New Body Color, "Navy Blue Mica"
Jan 9, 2026 10:23 JST
|
|
|
Fujitsu develops digital learning platform for JAL to support self-directed learning and training management
Jan 9, 2026 10:07 JST
|
|
|
Capital Margin Trade Announces the Launch of Practical Trading Tools Designed For Structured Market Execution
Jan 9, 2026 07:00 HKT/SGT
|
|
|
Military Metals Announces Buyback of 1% Royalty on Slovakian Portfolio
Jan 8, 2026 20:59 HKT/SGT
|
|
|
Hong Kong Tech Firms Win Big at CES 2026 with Frontier Tech Innovations to Draw Global Buyer Interest
Jan 8, 2026 19:31 HKT/SGT
|
|
|
Education & Careers Expo opens 22 January
Jan 8, 2026 16:29 HKT/SGT
|
|
|
Hall Chadwick to Convene Invitation-Only Capital Access Forum for APAC Corporates Exploring Global Capital Pathways
Jan 8, 2026 14:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
